Fertig Raymond M, Gamret A Caresse, Darwin Evan, Gaudi Sudeep
University of Miami, Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, Florida.
Dermatol Online J. 2017 Nov 11;23(11):13030/qt24k8q743.
The 5-α-reductase inhibitors finasteride and dutasteride are frequently used in the treatment of androgenetic alopecia and benign prostatichyperplasia. These drugs are effective at reducing levels of dihydrotestosterone, the primary androgen responsible for the pathogenesis of both these conditions. However, finasteride and dutasteride have also been shown to produce an increase in the incidence of sexual dysfunction, namely, impotence, decreased libido, and ejaculation disorder. The purpose of this study is to review the existing medical literature with regard to the sexual side effects of 5-α-reductase inhibitor therapy. This review is an extensive look at the sexual effects of 5-α-reductase inhibitors and compares outcomes for finasteride versus dutasteride in addition to comparing sexualside effects for each of the different dosages prescribed of finasteride and dutasteride.
5-α还原酶抑制剂非那雄胺和度他雄胺常用于治疗雄激素性脱发和良性前列腺增生。这些药物在降低二氢睾酮水平方面有效,二氢睾酮是导致这两种病症发病的主要雄激素。然而,非那雄胺和度他雄胺也已被证明会使性功能障碍的发生率增加,即阳痿、性欲减退和射精障碍。本研究的目的是回顾关于5-α还原酶抑制剂治疗的性副作用的现有医学文献。这篇综述广泛探讨了5-α还原酶抑制剂的性影响,并比较了非那雄胺与度他雄胺的治疗结果,此外还比较了非那雄胺和度他雄胺不同规定剂量下的性副作用。